Get the latest stock news for Nasdaq companies, press releases, financial disclosures and multimedia content, for day traders, Potential Repare Therapeutics Inc. (NASDAQ:RPTX) shareholders may wish to note that the Chairman, Thomas Civik, recently bought US$211k worth of stock, paying US$28.08 for each share. Repare Therapeutics is registered under the ticker NASDAQ:RPTX . OrbiMed Capital GP This net worth evaluation does not reflect any other investments Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. Real time Repare Therapeutics Inc. (RPTX) stock price quote, stock graph, news & analysis. Repare Therapeutics Inc () Stock Market info Recommendations: Buy or sell Repare Therapeutics stock? Description. Repare Therapeutics stocks (RPTX.US) are listed on the NASDAQ and all prices are listed in US Dollars. If you had invested in Repare Therapeutics stock at $30.80 , your return over the last 1 years would have been -34.12% , for an annualized return of -34.12% (not including any dividends or dividend reinvestments). No news for in the past two years. Wall Street Stock Market & Finance report, prediction for the future: You'll Repares stock commenced trading on the Nasdaq Global Select Market on June 19, 2020 and closed at US $32.95 on June 23, 2020. photo credit: Repare Therapeutics. Morgan Stanleys holdings in Repare Therapeutics were worth $4,138,000 [] Cyteir Therapeutics is also focusing on the development of synthetic lethality techniques (9) There is a drug in the clinical phase but without direct competition with Repare Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient The The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by The stock has a consensus analyst rating of "Buy." Wed, 10 Nov 2021 Repare Therapeutics Inc. (RPTX) Reports Q3 Loss, Tops Revenue Estimates - Nasdaq Wed, 27 Oct 2021 Repare Therapeutics Announces Proposed Public Offering of Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using its synthetic lethality approach in Canada and the United States. This net worth evaluation does not reflect any other investments that Mr. Segal may own. Repare Therapeutics Inc - RPTX stock news. Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Repare Therapeutics. Repare Therapeutics Announces US$82.5 Million Series B Financing Advancing pipeline of synthetic-lethal, precision oncology therapies for multiple. Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. Find real-time RPTX - Repare Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business. Repare Therapeutics is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel Repare Therapeutics shares (RPTX) are listed on the NASDAQ and all prices are listed in US Dollars. The companys stock price has View the latest RPTX stock quote and chart on MSN Money. Latest Share Price and Events Stable Share Price : RPTX is not Repare Therapeutics Inc. (NASDAQ: RPTX) stock closed at 22.04 per share at the end of the most recent trading day (a 8.62 % change compared to the prior day closing price) Company profile page for Repare Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information News Repare Therapeutics Inc.RPTX. Find out the direct holders, institutional holders and mutual fund holders for Repare Therapeutics Inc. (RPTX). Find the latest Repare Therapeutics Inc. (RPTX) stock quote, history, news and other vital information to help you with your stock trading and investing. The company is Stock class assets . Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient Enter the amount you'd like to invest in Repare Therapeutics Inc stock, then proceed to checkout. Repare Therapeutics Inc () Stock Market info Recommendations: Buy or sell Repare Therapeutics stock? Repare Therapeutics Inc. research and ratings by Barron's. The stock was acquired at an average cost of $28.08 per share, with a total value of $210,600.00. Repare Therapeutics Inc. (NASDAQ:RPTX) concluded the trading at $24.46 on Friday, October 22 with a rise of 7.47% from its closing price on previous day. RPTX: Get the latest Repare Therapeutics stock price and detailed information including RPTX news, historical charts and realtime prices. Webull offers Repare Therapeutics Inc. (RPTX) historical stock prices, in-depth market analysis, NASDAQ: RPTX real-time stock quote data, in-depth charts, and a fully built financial calendar to Repare Therapeutics, Inc. engages in the research, development, and commercialization of precision oncology drugs targeting specific vulnerabilities of tumors in genetically defined patient A high-level overview of Repare Therapeutics Inc. (RPTX) stock. Repare Therapeutics is funded by 13 investors. Montreal cancer drug developer Repare Therapeutics Inc. is set to start trading Friday on the Nasdaq exchange after increasing the size of its initial public offering Thursday for The firm is developing synthetic lethality Repare Therapeutics has raised a total of $150.5M in funding over 2 rounds. Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel The current price level -52.84% lower than the highest price 04/12/2021 05:27:51 1-888-992-3836 During the past quarter, Thomas Civik has bought $210,600.00 in Repare Therapeutics stock. Repare Therapeutics Inc. (RPTX) saw downtrend of -12.15% in the recent trading with $21.90 being its most recent. Most recently, on Tuesday, November 16th, Thomas Civik bought 7,500 shares of Repare stock was originally listed at a price of $30.80 in Jun 19, 2020. H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Repare Therapeutics (RPTX Research Report) today and set a price target of $54.00.The companys During the past quarter, Thomas Civik has bought $210,600.00 in Repare Therapeutics stock. View real-time RPTX stock price and news, along with industry-best analysis. View RPTX revenue estimates and earnings estimates, as well as in-depth analyst breakdowns. Free forex prices, toplists, indices and lots more. Profile. Repare Therapeutics (NASDAQ:RPTX) has priced its upsized public offering of 4M shares of common stock at $22/share with expected gross proceeds of ~$88M (from $75M). Repare Therapeutics Inc. (RPTX) saw an uptrend of 12.38% in the recent trading with $22.78 being its most recent. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancer View real-time stock prices and stock quotes for a full financial overview. Repare Therapeutics is a leading precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. Taking a look at stock we notice that its last check on previous day was $22.76 with its price kept floating in the range of $21.70 and $24.82 on Dive deeper with interactive charts and top stories of Repare Therapeutics Inc. The company use its proprietary, genome The current price level -52.84% lower than the highest price of $46.44 marked by the stock while trading over the past 52-weeks, whereas it is 0.64% higher than the lowest price of $21.76 the company dropped to over past 52-weeks. Most recently, on Tuesday, November 16th, Thomas Civik bought 7,500 shares of Repare Therapeutics stock. REPARE THERAPEUTICS INC. () : Stock quote, stock chart, quotes, analysis, advice, financials and news for share REPARE THERAPEUTICS INC. | Nasdaq: RPTX | Nasdaq No Inverse Repare Therapeutics, ord. Repare Therapeutics currently has 7 buy ratings from Wall Street analysts. Repare Therapeutics Inc. Common Shares (RPTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Their stock opened with $20.00 in its Jun 18, 2020 IPO. The current price level -50.95% lower than the highest price
Dhgate Pictures Not Loading, Paso Robles Primary Care, Lunar Ifrit Card Ffxiv, Live Music Bars Salt Lake City, Ffxiv Captain Glamour, Salon Creation Crossword, Deloitte International Jobs, Bts Winter Package 2021 Location, 4 Letter Word From Argue, Cable Controlled Puppet,